Claresa Levetan is an Endocrinology/Metabolic physician affiliated with American Board of Internal Medicine. OpenAlex indexes 38 publications with 1,589 citations (h-index 16); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
419 S Broad St Unit 4
Lansdale, PA 194463703
Telephone
267-429-2561Provider last certified this registry record 6 May 2026.
Clinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
35 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Medtronic, Inc.Program year202517 payments
- Abbott LaboratoriesProgram year20258 payments
- Mannkind CorporationProgram year20255 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
62.1%Insulin Analog24.1%Novolog Flexpen27%Tresiba Flextouch U-10025%Lantus Solostar14%Tresiba Flextouch U-20013%Novolog5%Humalog Kwikpen U-1004%Admelog Solostar3%Basaglar Kwikpen U-1002%Insulin Lispro Kwikpen U-1002%Insulin Aspart Flexpen2%Humalog2%Soliqua 100-332%Part D<11 patientsGLP-1 receptor agonist20.4%Mounjaro48%Ozempic40%Trulicity8%Rybelsus4%Part D<11 patients+ 5 more classes in this area
Hormonal (systemic)
23.1%l-Thyroxine19.1%Levothyroxine Sodium68%Synthroid32%Part D≥77 patientsThyroid Hormone Synthesis Inhibitor2.1%Methimazole100%Part D≥15 patients+ 3 more classes in this area
Cardiovascular
12.4%Statin8.2%Atorvastatin Calcium59%Rosuvastatin Calcium28%Simvastatin13%Part D<11 patientsOther lipid modifying agents1.2%Vascepa55%Icosapent Ethyl45%Part D<11 patients+ 5 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- ISLET Neogenesis in Man Without the Need for Transplants
EC Endocrinology and Metabolic Research
2021 - Islet Neogenesis Therapy from Endogenous Pancreatic Stem Cells without Transplantation: Will Type 1 and Type 2 Diabetes Soon be Diseases of the Past?
Journal of Diabetes and Treatment
2017 - Proposal for generating new beta cells in a muted immune environment for type 1 diabetes
Diabetes/Metabolism Research and Reviews
2013
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Jens J. Holst
University of Copenhagen
Victor Montori, MD
Mayo Clinic
Daniel J. Drucker
University of Toronto
Kenneth Cusi, MD
University of Florida College of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”